This study will look at whether emtricitabine is as safe and effective as abacavir (ABC) when taken with stavudine (d4T) and efavirenz (EFV) in patients who have never taken anti-HIV drugs.
Patients are randomized to receive open-label emtricitabine or ABC in combination with stavudine and efavirenz. Viral load and CD4+ cell counts are compared at Weeks 24 and 48. Patients are followed for 48 weeks.
Study Type
INTERVENTIONAL
Purpose
TREATMENT
Ctr for AIDS Research / Education and Service (CARES)
Sacramento, California, United States
San Francisco Veterans Administration Med Ctr
San Francisco, California, United States
Gary Richmond MD
Fort Lauderdale, Florida, United States
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Northstar Med Clinic
Chicago, Illinois, United States
South Jersey Infectious Diseases Inc
Somers Point, New Jersey, United States
North Shore Univ Hosp / Div of Infectious Diseases
Manhasset, New York, United States
Univ of Texas Southwestern Med Ctr of Dallas
Dallas, Texas, United States
Houston Clinical Research Network
Houston, Texas, United States
Univ of Texas / Med School at Houston
Houston, Texas, United States
Univ of Texas Health Sciences Ctr
San Antonio, Texas, United States